(Q38056832)

27 August 2017

GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia (English)

1 reference

27 August 2017

0 references

1 reference

Ines M Macias-Perez

1

1 reference

PubMed ID

23114654

27 August 2017

Ian W Flinn

series ordinal

2

1 reference

27 August 2017

1 March 2013

1 reference

Current hematologic malignancy reports

27 August 2017

1 reference

27 August 2017

8

1 reference

27 August 2017

1

1 reference

27 August 2017

22-27

1 reference

https://scigraph.springernature.com/pub.10.1007/s11899-012-0142-1

27 August 2017

0 references

cites work

Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Sex differences in incidence and outcome of chronic lymphocytic leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Familial CLL: genes and environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

The microenvironment in mature B-cell malignancies: a target for new treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Phosphoinositide signalling in cancer: beyond PI3K and PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

The emerging mechanisms of isoform-specific PI3K signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Exploring the specificity of the PI3K family inhibitor LY294002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Targeting the PI3K signaling pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

p110δ, a novel phosphoinositide 3-kinase in leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0142-1

From pathogenesis to treatment of chronic lymphocytic leukaemia

21 January 2018

1 reference

12 December 2020

Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase

1 reference

12 December 2020

Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.

1 reference

12 December 2020

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia

1 reference

12 December 2020

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

1 reference

12 December 2020

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

1 reference

12 December 2020

Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice

1 reference

12 December 2020

Phosphoinositide 3-kinase signalling pathways

1 reference

12 December 2020

10.1007/S11899-012-0142-1

Identifiers

DOI

1 reference

PubMed ID

23114654

Dimensions Publication ID

27 August 2017

0 references

1 reference

PubMed ID

23114654